Weider
This article was originally published in The Tan Sheet
Executive Summary
Firm's Schiff Move Free joint supplement sales fell 2.9% in the first quarter versus the prior year period which is "unacceptable, but does indicate we are starting to stabilize the brand," CEO Bruce Wood comments in Sept. 25 earnings call. In March, Weider implemented a brand-building initiative for Move Free that included over $12 mil. in ad spending to spur its sales (1"The Tan Sheet" Aug. 18, 2003, p. 13). Wood expects low, single-digit Move Free growth in Weider's 2004 fiscal year, driven by double-digit growth at year-end. The exec also says Weider plans to launch new products "branching into new broad human condition areas, an example being cardiovascular health," in 2005...
You may also be interested in...
Weider Move Free Advertising Strategy Key To Earnings Improvement
Weider says a recently launched brand-building initiative for its Schiff division's Move Free joint supplement product line will help return the company to positive earnings in the coming year
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.